Literature DB >> 15926760

Impairment in work productivity and health-related quality of life in patients with IBS.

Bonnie B Dean1, Daniel Aguilar, Victoria Barghout, Kristijan H Kahler, Feride Frech, David Groves, Joshua J Ofman.   

Abstract

Irritable bowel syndrome (IBS) is a long-term and episodic medical disorder shown to have an impact on work productivity and health-related quality of life (QOL). The objective of this study was to assess the impact of IBS on work productivity and on health-related QOL in an employed population in the United States and to quantify the cost of these factors to the employer. A 2-phase survey was sent to the workforce of a large US bank to assess the presence of IBS among employees and to measure their work productivity (absenteeism [time lost from work] and presenteeism [reduced productivity at work]) and health-related QOL. Forty-one percent of the 1776 employees responding to both phases of the survey met the Rome II criteria for IBS. Employees with IBS reported a 15% greater loss in work productivity because of gastrointestinal symptoms than employees without IBS and had significantly lower Medical Outcomes Study Short Form 36 (SF-36) scores than those without IBS. IBS was associated with a 21% reduction in work productivity, equivalent to working less than 4 days in a 5-day workweek. Employees with IBS also had significantly lower scores on all domains of the SF-36, indicating poorer functional outcomes. Reduced work productivity and diminished QOL of these magnitudes may have substantial financial impact on employers.

Entities:  

Mesh:

Year:  2005        PMID: 15926760

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  70 in total

1.  Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations.

Authors:  Eric L Garland; Susan A Gaylord; Olafur Palsson; Keturah Faurot; J Douglas Mann; William E Whitehead
Journal:  J Behav Med       Date:  2011-12-08

Review 2.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

Review 3.  Employee health and presenteeism: a systematic review.

Authors:  Alyssa B Schultz; Dee W Edington
Journal:  J Occup Rehabil       Date:  2007-07-25

4.  Natural history of upper extremity musculoskeletal symptoms and resulting work limitations over 3 years in a newly hired working population.

Authors:  Bethany T Gardner; Ann Marie Dale; Alexis Descatha; Bradley Evanoff
Journal:  J Occup Environ Med       Date:  2014-06       Impact factor: 2.162

5.  Obesity and irritable bowel syndrome: a comprehensive review.

Authors:  Octavia Pickett-Blakely
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

6.  I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.

Authors:  Vicente Lorenzo-Zúñiga; Elba Llop; Cristina Suárez; Beatriz Alvarez; Luis Abreu; Jordi Espadaler; Jordi Serra
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 7.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

8.  Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial.

Authors:  Massimo Vincenzi; Irene Del Ciondolo; Elisa Pasquini; Katia Gennai; Barbara Paolini
Journal:  J Transl Int Med       Date:  2017-06-30

9.  Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.

Authors:  Johanna Iturrino; Michael Camilleri; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Liver Dis       Date:  2013-10-04       Impact factor: 4.088

10.  Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?

Authors:  Savio C Reddymasu; Sandra Sostarich; Richard W McCallum
Journal:  BMC Gastroenterol       Date:  2010-02-22       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.